DR ANTHONY MELVIN CRASTO,WorldDrugTracker, helping millions, A 90 % paralysed man in action for you, I am suffering from transverse mylitis and bound to a wheel chair,With death on the horizon, This will not stop me, Gods call only..........
DR ANTHONY MELVIN CRASTO Ph.D ( ICT, Mumbai) , INDIA 29Yrs Exp. in the feld of Organic Chemistry,Working for GLENMARK PHARMA at Navi Mumbai, INDIA. Serving chemists around the world. Helping them with websites on Chemistry.Million hits on google, world acclamation from industry, academia, drug authorities for websites, blogs and educational contributio
n

Saturday 9 April 2016

Susanta Samajdar Research Director at Aurigene Discovery Technologies


Susanta Samajdar

Susanta Samajdar

Research Director at Aurigene Discovery Technologies



Aurigene Discovery Technologies Limited
39-40, KIADB Industrial Area Electronic City Ph II, Hosur Road
Bangalore , Karnataka 560100
India



Susanta Samajdar, Ph.D., Research Director, Medicinal Chemistry, Aurigene Discovery Technologies Limited Susanta Samajdar received his Ph.D. in Synthetic Organic Chemistry from Indian Association for the Cultivation of Science (IACS), Kolkata and subsequently moved to MD Anderson Cancer Center for a Post-Doctoral training on anti-cancer drug discovery. He has over 12 years of synthetic and Medicinal Chemistry research experience in Indian Industries. Susanta has experience in leading multi-disciplinary drug discovery teams that successfully delivered several preclinical development candidates. He has elaborate experience in working with Kinases and other target classes like GPCRs, Ion channels, Proteases and NHRs, across different therapeutic areas like Oncology, Pain and Inflammation and Neurosciences.

 Susanta Samajdar
links
https://www.facebook.com/susanta.samajdar
https://www.researchgate.net/profile/Susanta_Samajdar
https://profiles.google.com/114544433547394350208/about
https://in.linkedin.com/in/susanta-samajdar-b6025821
http://selectbioindia.net/proceedings/Report%20MCI2015.pdf

Susanta Samajdar, Research Director, Aurigene Discovery Technologies Limited

Dr. Susanta Samajdar received his PhD in Synthetic Organic Chemistry from Indian Association for the Cultivation of Science (IACS), Kolkata and subsequently moved to MD Anderson Cancer Center for a Post-Doctoral Research on anti-cancer drug discovery. He has over 15 years of synthetic and Medicinal Chemistry research experience in Indian Industries. Susanta has experience in leading multi-disciplinary drug discovery teams that successfully delivered several preclinical development candidates. He has experience in working with various target classes including GPCRs, Ion channels, Proteases, Kinases, NHRs, Epigenetics etc across different therapeutic areas like Oncology, Pain and Inflammation, Metabolic Disorders and Neurosciences. He has more than 20 publications and several patents to his credit.

Experience


Research Director in Medicinal Chemistry

Aurigene Discovery Technologies
– Present (4 years 2 months)Bangalore

Director

Jubilant Biosys
(9 months)Bangalore

Associate Director

Jubilant Biosys
(4 years 11 months)Bangalore
Drug Discovery Medicinal Chemistry

Scientific Manager

Syngene International
(4 years)





Education


Kandi Raj College

BSc, Chemistry



 

 Abstract Image


Simple Synthesis of Substituted Pyrroles

The University of Texas, M. D. Anderson Cancer Center, Department of Molecular Pathology, Box 89, 1515 Holcombe Boulevard, Houston, Texas 77030 %bbanik@mail.mdanderson.org
J. Org. Chem., 2004, 69 (1), pp 213–216



Journal: Australian Journal of Chemistry - AUST J CHEM , vol. 63, no. 1, 2010





Abstract C190: Potent and selective inhibition of CDK7 by novel covalent inhibitors

Abstracts: AACR-NCI-EORTC International Conference: Molecular Targets and Cancer Therapeutics; November 5-9, 2015; Boston, MA

Abstract

Cyclin-dependent kinase 7 (CDK7) is an important constituent of the cellular transcriptional machinery, where it phosphorylates the C-terminal domain (CTD) of RNAP polymerase II (RNAPII). Because many tumor types are critically dependent on transcription for maintenance of their oncogenic state, pharmacological modulation of CDK7 kinase activity is considered as an approach to treat cancer. Multiple series of CDK7 inhibitors were identified by iterative medicinal chemistry efforts and SAR based approach. Early compounds were optimized towards attaining good physicochemical properties, high potency, good selectivity and desirable pharmacokinetic profile to achieve anti-tumor activity. We have identified compounds from two distinct chemical series that are highly potent in inhibiting CDK7 in biochemical assays. These inhibitors demonstrate time-dependent inhibition of CDK7 indicating covalent nature of binding. The compounds showed potent anti-proliferative activity in cell lines derived from various tumor types and this was accompanied by CDK7 modulation in cells as monitored by pS5RNAPII levels. They have excellent drug-like characteristics including solubility, permeability, metabolic stability and good oral bioavailability. In a broad panel of kinases (332 kinase), selected compounds from both series showed good selectivity profile. Tolerability and efficacy studies are ongoing with selected early leads to test their impact on tumor growth inhibition in xenograft models. We have identified novel and selective CDK7 covalent inhibitors from two series with desirable drug-like properties, which are being evauated for anti-tumor activity in xenograft models.
Citation Format: Ramulu Poddutoori, Leena K. Satyam, Girish Daginakatte, Subhendu Mukherjee, Sivapriya Marappan, Sreevalsam Gopinath, Raghuveer Ramachandra, Anirudha Lakshminarasimhan, Manoj Pothuganti, Shilpa Nayak, Nandish C, Chandranath Naik, Ravindra MV, Madhu Dabbeeru, Thomas Antony, Chetan Pandit, Murali Ramachandra, Shekar Chelur, Susanta Samajdar. Potent and selective inhibition of CDK7 by novel covalent inhibitors. [abstract]. In: Proceedings of the AACR-NCI-EORTC International Conference: Molecular Targets and Cancer Therapeutics; 2015 Nov 5-9; Boston, MA. Philadelphia (PA): AACR; Mol Cancer Ther 2015;14(12 Suppl 2):Abstract nr C190.




 

Event Abstract

Discovery of potent and selective retinoid related orphan receptor gamma (RORγ) inverse agonists for the treatment of Th17 mediated diseases

  • 1 Aurigene Discovery Technologies Ltd., India
Background: Th17 cells play a key pro-inflammatory role in a variety of autoimmune diseases. The nuclear hormone receptor RORγ controls the differentiation of Th17 cells and expression of IL-17.
Methods: Novel RORγ inverse agonists were designed using structure and knowledge based methods. Compounds were screened in a RORγ radio-ligand binding assay using 3H 25- Hydroxycholesterol, as well as in a cell based reporter assay to demonstrate inverse agonism. Selected compounds were screened against RORα to evaluate selectivity. Crystal structure of RORγ in complex with known inverse agonists as well as novel compounds, were solved. Th17 differentiation assay was developed using primary mouse CD4+ve T-cells to determine functional effect of the compounds. Pharmacokinetic profile in mice was determined for selected compounds.
Results: Novel hits from multiple structural classes have been identified, with IC50 in the range of 5 – 500 nM in binding assay. Compounds from the lead series demonstrated good activity (< 1 μM) in reporter assay. Co-crystal structure of novel compounds clearly showed the mode of binding. Several compounds demonstrated > 10 fold selectivity against RORα in a reporter assay. Compounds from multiple series have shown significant inhibition of IL-17 release from differentiated Th17 cells. Lead compounds have shown good pharmacokinetic properties in mice.
Conclusions: We have identified novel and structurally diverse small molecule inverse agonists of
RORγ. Selectivity against RORα and cell based activity has been demonstrated for compounds from multiple series. Relevant efficacy models have been established and profiling of lead compounds in these models in on-going.
Keywords: RORγ, Autoimmune Diseases, Th17 Cells, IL-17, Psoriasis
Conference: 15th International Congress of Immunology (ICI), Milan, Italy, 22 Aug - 27 Aug, 2013.
Presentation Type: Abstract
Topic: Immune-mediated disease pathogenesis
Citation: Nellore K, Bejugam M, Ramanathan A, Mukherjee S, Lakshminarasimhan A, Dodheri SS, Rao N, Damarla R, Samajdar S and Subramanya H (2013). Discovery of potent and selective retinoid related orphan receptor gamma (RORγ) inverse agonists for the treatment of Th17 mediated diseases. Front. Immunol. Conference Abstract: 15th International Congress of Immunology (ICI). doi: 10.3389/conf.fimmu.2013.02.00678
Received: 13 Jun 2013; Published Online: 22 Aug 2013.
* Correspondence: Dr. Hosahalli Subramanya, Aurigene Discovery Technologies Ltd., Bangalore, India, hosahalli_s@aurigene.com


Asymmetric synthesis of anticancer β-lactams via Staudinger reaction

  • Authors:
    • Bimal K. Banik
    • Susanta Samajdar
    • Frederick F. Becker
  • View Affiliations
  • Published online on: Monday, March 1, 2010
  • Pages: 319-321 DOI: 10.3892/mmr_00000259

Abstract

This study describes the symmetric synthesis of novel β-lactams derived from chrysene directed towards their SAR, as well as their biological activities against several cancer cell lines in vitro. To our knowledge, this is the first report on the synthesis and biological evaluation of optically active anticancer β-lactams. That these anticancer effects are not uniform against all tumor lines suggests that the target of the action of these compounds is highly specific.


//////////////






 à¤¸ुकून उतना ही देना प्रभू, जितने से जिंदगी चल जाये। औकात बस इतनी देना, कि औरों का भला हो जाये।
DRUG APPROVALS BY DR ANTHONY MELVIN CRASTO …..FOR BLOG HOME CLICK HERE



Join me on Linkedin

View Anthony Melvin Crasto Ph.D's profile on LinkedIn

Join me on Facebook FACEBOOK
Join me on twitterFollow amcrasto on Twitter
Join me on google plus Googleplus
Join me on Researchgate

Anthony Melvin Crasto Dr.

  amcrasto@gmail.com

09b37-misc2b027LIONEL MY SON
He was only in first standard in school when I was hit by a deadly one in a million spine stroke called acute transverse mylitis, it made me 90% paralysed and bound to a wheel chair, Now I keep him as my source of inspiration and helping millions, thanks to millions of my readers who keep me going and help me to keep my son happy

सुकून उतना ही देना प्रभू, जितने से
जिंदगी चल जाये।
औकात बस इतनी देना,
कि औरों का भला हो जाये।
Read all about Organic Spectroscopy on ORGANIC SPECTROSCOPY INTERNATIONAL